Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-28
DOI
10.1007/s00280-019-03875-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
- (2018) Robert J. Kreitman et al. BLOOD
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Adverse Reactions to Biologic Therapy
- (2017) Sheenal V. Patel et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
- (2016) Michael R. Grever et al. BLOOD
- Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
- (2016) Dai Chihara et al. BRITISH JOURNAL OF HAEMATOLOGY
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hairy cell leukaemia-variant: Disease features and treatment
- (2015) Estella Matutes et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Immunoconjugates in the management of hairy cell leukemia
- (2015) Robert J. Kreitman et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
- (2015) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria
- (2013) Haipeng Shao et al. LEUKEMIA RESEARCH
- CD22 ligation inhibits downstream B cell receptor signaling and Ca2+flux upon activation
- (2012) N. Sieger et al. ARTHRITIS AND RHEUMATISM
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence
- (2011) Monica Else et al. LEUKEMIA & LYMPHOMA
- Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
- (2009) Monica Else et al. BRITISH JOURNAL OF HAEMATOLOGY
- CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
- (2009) R. F. Alderson et al. CLINICAL CANCER RESEARCH
- Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
- (2008) R. Zenhausern et al. HAEMATOLOGICA
- Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study
- (2008) L Orsi et al. OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started